SOUTH SAN FRANCISCO, CA--(Marketwire - December 31, 2007) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced the initiation of an open-label, non-randomized Phase I/II clinical trial designed to evaluate ispinesib monotherapy as a first-line treatment in chemotherapy-naïve patients with locally advanced (Stage IIIB) or metastatic (Stage IV) breast cancer.
